2 results
Approved WMORecruiting
To increase the major pathological response rate (< 10% vital tumor cells) to neoadjuvant treatment by integrating both trastuzumab and pertuzumab into perioperative chemotherapy for HER-2 positive, resectable gastric cancer.
Approved WMOPending
In this study, we to confirm the cuff design and make sure it works. Aspects such as safety and ease of use are also evaluated.